BioCentury
ARTICLE | Clinical News

Velcade bortezomib: Phase III data

November 15, 2010 8:00 AM UTC

The Phase III HOVON-65/GMMG-HD4 trial in 626 patients with newly diagnosed symptomatic MM showed that the Velcade-based treatment regimen led to superior PFS at 36 months vs. the standard chemotherapy treatment regimen (48% vs. 42%, p=0.047). Patients received induction therapy with 3 cycles of Velcade, Doxil doxorubicin and dexamethasone, followed by high-dose melphalan and maintenance therapy with Velcade, or induction therapy with 3 cycles of standard vincristine, adriamycin and dexamethasone chemotherapy, followed by high-dose melphalan and maintenance therapy with thalidomide. Velcade-based therapy also led to improved rates of OS at 36 months vs. standard chemotherapy (78% vs. 71%, p=0.048), as well as rates of nCR/CR, VGPR and PR (50%, 75% and 92%, respectively, vs. 38%, 61% and 87%). Data will be presented at the American Society of Hematology meeting in Orlando in December. ...